Clinical Trial Update: A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety, efficacy, and biomarker response of BMS-986165 in adults with moderate to severe ulcerative colitis has completed. Results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• BMS-986165

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Colitis, Ulcerative | Phase 2 | Status: COMPLETED | Results posted: 2024-07-12